Report of Foreign Issuer (6-k)
December 05 2016 - 12:11PM
Edgar (US Regulatory)
United
States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of December, 2016
Commission File Number: 001-35892
GW
PHARMACEUTICALS PLC
(Translation of registrant’s name
into English)
Sovereign
House
Vision
Park
Histon
Cambridge
CB24 9BZ
United
Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Other Events
On December 5, 2016, GW
Pharmaceuticals plc (the “Company”) issued a press release announcing its fourth quarter and year-end 2016
financial results and operational progress and details of a conference call to be held at 8:00 a.m. EST on December 5, 2016
to discuss the results. The press release is attached as Exhibit 99.1 and is incorporated by reference herein.
On December 5, 2016, the Company issued
a press release announcing additional positive Epidiolex® (cannabidiol or CBD) Phase 3 data in poster presentations at the
70th Annual Meeting of the American Epilepsy Society. The press release is attached as Exhibit 99.2 and is incorporated by reference
herein. The posters are also available from the Investors section of the Company’s website.
The information contained in Exhibits 99.1
and 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, unless expressly set forth by specific reference in such a filing.
Exhibits
|
|
|
99.1
|
|
Press release dated December 5, 2016
|
99.2
|
|
Press release dated December 5, 2016
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
GW Pharmaceuticals plc
|
|
|
|
|
By:
|
/s/ Adam George
|
|
Name:
|
Adam George
|
|
Title:
|
Chief Financial Officer
|
|
|
|
Date: December 5, 2016
|
|
|